Trial Profile
CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs CER 001 (Primary)
- Indications Acute coronary syndromes; Atherosclerosis
- Focus Therapeutic Use
- Acronyms CHI SQUARE
- Sponsors ABIONYX Pharma; Cerenis Therapeutics
- 29 Apr 2014 Primary endpoint 'Plaque-volume' has not been met according to results published in European Heart Journal.
- 29 Apr 2014 Results published in the European Heart Journal.
- 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.